{
    "title": "Boost for AstraZeneca as its breast cancer drug Lynparza is given the green light from European regulators",
    "url": "https://www.dailymail.co.uk/money/markets/article-11082443/AstraZeneca-breast-cancer-drug-Lynparza-approved-EU-regulators.html",
    "date": "2022-08-04",
    "keywords": [
        "cancer",
        "drug",
        "approval",
        "breast",
        "commission",
        "type",
        "earlystage",
        "eu",
        "share",
        "fund",
        "pipeline",
        "lynparza",
        "risk",
        "cent",
        "use",
        "form",
        "research",
        "boss",
        "money",
        "month",
        "investment",
        "account",
        "fee",
        "treatmentsthe",
        "cancerthe",
        "phase",
        "trial",
        "june",
        "death",
        "era",
        "care",
        "europe",
        "tutt",
        "professor",
        "oncology",
        "institute",
        "london",
        "trialin",
        "britain",
        "die",
        "year",
        "payment",
        "group",
        "merck",
        "co",
        "treatmentastrazeneca",
        "news",
        "position",
        "company",
        "stock",
        "market",
        "value",
        "triplewhammy",
        "purse",
        "inflation",
        "incoming",
        "task",
        "diageo",
        "ivan",
        "rise",
        "article",
        "diy",
        "shot",
        "arm",
        "purchase",
        "access",
        "treatment",
        "lymphoma",
        "blood",
        "firm",
        "daiichi",
        "sankyo",
        "capital",
        "isa",
        "trade",
        "community",
        "model",
        "affiliate",
        "product",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}